Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups
Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups
Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
-
Genre
Tous
Aire thérapeutique :
Dermatologie
Maladie :
Psoriasis
Traitement :
Tazarotene
Phase :
Phase II
Date de début de l'étude :
28 Avril 2005
End date :
08 Mai 2006
Identifiant de l'essai :
R00002 VE 201
Identifiant EudraCT/CTIS :
2004-004825-87
Envoyer par email